Amplification‐Free Multi‐RNA‐Type Profiling for Cancer Risk Stratification via Alternating Current Electrohydrodynamic Nanomixing. Issue 17 (12th March 2018)

• Record Type: Journal Article
• Authors: Koo, Kevin M.; Dey, Shuvashis; Trau, Matt
• Is Part Of: Small. Volume 14:Issue 17(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-03-12
• Subjects: electrohydrodynamic -- liquid biopsy -- prostate cancer -- risk stratification -- RNA biomarkers; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.201704025
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract: Simultaneous analysis of messenger RNA (mRNA), microRNA (miRNA), and long noncoding RNA (lncRNA)—multi‐RNA‐type profiling—is increasingly crucial in cancer diagnostics. Yet, rapid multi‐RNA‐type profiling is challenging due to enzymatic amplification reliance and RNA‐type‐dependent characteristics. Here, a nanodevice is reported to uniquely use alterable alternating current electrohydrodynamic (ac‐EHD) forces to enhance probe–target hybridization prior to direct native RNA target detection, without target amplification or surface functionalization. To exemplify clinical applicability, noninvasive screening of next‐generation prostate cancer (PCa) RNA biomarkers (of different types) in patient urine samples is performed. A strong correlation between multi‐RNA‐type expression and aggressive PCa is found, and the nanodevice performance is statistically evaluated. It is believed that this miniaturized system exhibits great potential for cancer risk stratification via multi‐RNA‐type profiling. Abstract : Adjustable fluidic nanomixing is used to enable rapid universal detection of various RNA types without target amplification. Alterable alternating current electrohydrodynamic nanomixing and direct detection of native RNA targets is achieved on an integrated nanodevice. Multi‐RNA‐type profiling is performed in cancer patient samples to showcase the promise for noninvasive clinical diagnosis, prognosis, and treatment monitoring.